Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUGAR-DM-HF
2016-003719-37Phase 3Unknown
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin in type 2 diabetes mellitus (T2DM), prediabetes, chronic heart failure (CHF) and 1 more, sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Change in cardiac structure and function by MRI. Status: unknown.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)prediabeteschronic heart failure (CHF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2016-003719-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003719-37.